 |
|
||
 |
|||
       |
|||
|
|||||||||
|
|
 |
Danilo Perrotti
Danilo Perrotti, MD, PhD 860 Biomedical Research Tower 460 W. 12th St Columbus, OH 43210
Perrotti's CV ckm.osu.edu/sitetool/sites/humancancergeneticspublic/documents/DaniloPerrottiCVMARCH.doc
Research Interests 1. Bellon T#, D. Perrotti# and B. Calabretta. Granulocytic differentiation of normal hematopoietic precursor cells induced by the transcription factor PU.1 correlates with negative regulation of the c-myb promoter. Blood,.90(5):1828-1839,1997. (#): Equal contribution
2. D. Perrotti#, Bonatti S., Trotta R., Martinez R., Skorski T., Salomoni P., Grassilli E., Iozzo R.V., Cooper D.R. and B. Calabretta. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J. 17 (15): 4442-4455, 1998.
3. Perrotti D#., Iervolino A., Cesi V., Cirinna’ M., Lombardini S., Grassilli E., Bonatti S., Claudio P.P and B. Calabretta. BCR/ABL prevents c-Jun-mediated and proteasome-dependent TLS/FUS proteolysis through a PKCbII-dependent pathway. Mol. Cell. Biol,20(16): 6159-69,2000.
4. Perrotti D#, Cesi V, Trotta R., Guerzoni C, Santilli G., Campbell K., Iervolino A., Condorelli F., Gambacorti-Passerini C, Caligiuri MA. and B. Calabretta. BCR/ABL suppresses C/EBPa expression through the translation inhibitory activity of the hnRNP E2. Nature Genetics,30: 48-58, 2002
5. Iervolino A., G. Santilli, R. Trotta, C. Guerzoni, V. Cesi, A. Bergamaschi, C. Gambacorti-Passerini, B. Calabretta, and D. Perrotti. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol. Cell. Biol. 22:2255-66, 2002.
6. Trotta, R., T. Vignudelli, O. Candini, R. V. Intine, L. Pecorari, C. Guerzoni, G. Santilli, M.W. Byrom, S. Goldoni, L.P. Ford, M. A. Caligiuri, R.J. Maraia, D. Perrotti*, and B. Calabretta. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell,3:145-60.2003
7. Keeshan K., G. Santilli, F. Corradini, D. Perrotti* and B. Calabretta. The transcriptional activation function of C/EBPa ?is required for induction of granulocytic differentiation. Blood, 103:1267-75, 2003.
8. Neviani P., Santhanam R., Trotta R., Notari M., Blaser B.W., Liu S., Mao H, Chang JS, Galietta A, Uttam A, Roy D.C., Valtieri M., Bruner-Klisovic R., CaligiuriM.A., Bloomfield C.D., Marcucci G., and D. Perrotti*. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell.;8:355-68, 2005
9. Notari M., Neviani P., Santhanam R., Galietta A, Chang JS., Blaser B.W., Willis A.E., Roy D.C., Caligiuri M.A., Marcucci G. and D. Perrotti*. A MAPK/hnRNP K pathway controls BCR/ABL oncogenic potential by regulating c-myc mRNA translation. Blood,107:2507-16, 2006
10. C. Guerzoni, M. Bardini, S. Mariani, G. Ferrari-Amorotti, M.L. Panno,P. Neviani, Y. Zhang, R. Martinez, D. Perrotti, and B. Calabretta.Inducible activation of C/EBPb, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood.;107:4080-9, 2006
11. Chang JS., SanthanamR., Trotta R., Neviani P., Eiring A., Briercheck E., Ronchetti M., Roy DC., Calabretta B., Caligiuri MA and D. Perrotti. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP E2-dependent suppression of C/EBPa-driven Myeloid Differentiation. . Blood. 110(3):994-1003, 2007
12. Galietta A., Gunby R., Stano P., Carniti C., Bach A.i, Tartar C., Tucker P., Huang C., Colombo E., Pulford K., Puttini M., Piazza R., Ruchatz H., Perrotti D., and Gambacorti-Passerini C. NPM/ALK Binds and Phosphorylates the RNA/DNA Binding Protein PSF in Anaplastic Large Cell Lymphoma. Blood 110(7): 2600-9, 2007
13. Liu Q., Zhao X., Frissora F, Ma Y., Santhanam R., Jarjoura D., Lehman A., Perrotti D, Chen C-S, Dalton JT, Muthusamy N. and Byrd JC. FTY720 Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma by a PP2A dependent mechanism. Blood Aug. 2007
14. Neviani P., Santhanam R., Oaks J., Eiring A., Notari M., Blaser BW., Liu S., Trotta R., Muthusamy N., Verrills, N., Gambacorti-Passerini C., Druker BJ., Cortes J., Marcucci G., Chen CS, Roy DC., Caligiuri MA., Bloomfield CD., Byrd J and D. Perrotti*. FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL. J Clin. Invest., 117(9):2408-2421, 2007.
15. Trotta R., Dal Col J, Allard J., Neviani P., Santhanam R., Mao H., Becknell B, Yu J, Modi A., Blaser BW, Perrotti D*. and Caligiuri MA*. The PP2A Inhibitor SET Regulates Natural Killer Cells IFN-{gamma} Production. J. Exp. Med. 204(10):2397-405, 2007. (*: equal senior contribution)
16. Thomas EK., Cancelas JA., Chae H-D., Cox AD., Keller PJ., Perrotti D., Neviani P., Druker BJ, Setchell KDR, Zheng Y., Harris EC. and D.A Williams. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell, 12(5):467-78, 2007.
17. Eiring A., Oaks J., Neviani P., Chang JS., Notari M., Santhanam R., Willis W., Roy DC., Volinia S., Marcucci G., Caligiuri MA., Leone GW and Perrotti D*. Identification of Novel Posttranscriptional Targets of BCR/ABL Oncoprotein by Ribonomics: Role of E2F3 in BCR/ABL leukemogenesis. Blood. 2008;111(2):816-28..
18. Trotta R, Col JD, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J 2nd, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J. Immunol.181(6):3784-92, 2008
19. Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, Perrotti D and Arlinghaus RB. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene28(14):1669-81, 2009.
20. Eiring AM., Neviani P. Garton C., Spizzo R., Liu S., Oaks JJ., Hickey C., Santhanam R., Harb JG., Chandler JC., Andino R., Cortes J., Hokland P., Huettner CS, Bhatia R., Roy DC., Caligiuri MA, Marcucci G., Garzon R., Croce CM, Calin GA., and Perrotti D. A non-canonical decoy binding activity of miR-328 controls hnRNP-E2 translation inhibitory function in leukemic blasts. Cell 140(5):652-65, 2010.
|
|
|
|
